MLNM completes Phase II LDP-341 enrollment

Millennium (MLNM) completed enrollment of 75 patients in an open-label Phase II trial of its LDP-341 (formerly PS-341) proteasome inhibitor to treat multiple myeloma. The trial was designed to assess ...